15 analysts have expressed a variety of opinions on Vertex Pharmaceuticals (NASDAQ:VRTX) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 5 | 4 | 0 | 1 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 0 | 1 | 0 | 0 |
| 2M Ago | 3 | 4 | 1 | 0 | 0 |
| 3M Ago | 2 | 1 | 1 | 0 | 1 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $500.53, a high estimate of $600.00, and a low estimate of $376.00. Witnessing a positive shift, the current average has risen by 8.29% from the previous average price target of $462.20.
Breaking Down Analyst Ratings: A Detailed Examination
Login or create a forever free account to read this news
Sign up/Log in
